Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – B. Riley upped their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will earn ($3.70) per share for the year, up from their prior forecast of ($5.60). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q4 2025 earnings at ($0.92) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($3.27) EPS.
A number of other brokerages also recently commented on CRBP. HC Wainwright restated a “buy” rating and set a $50.00 price objective (down from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Wedbush restated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. William Blair began coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday, March 6th. Finally, Jefferies Financial Group cut their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $59.13.
Corbus Pharmaceuticals Stock Up 2.5 %
CRBP opened at $6.96 on Monday. The company’s 50-day moving average price is $9.32 and its 200 day moving average price is $18.10. Corbus Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $61.90. The firm has a market cap of $84.77 million, a price-to-earnings ratio of -1.48 and a beta of 2.63.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.24.
Institutional Investors Weigh In On Corbus Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. Vestcor Inc purchased a new position in Corbus Pharmaceuticals in the 3rd quarter worth about $64,000. Wells Fargo & Company MN boosted its holdings in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 2,195 shares during the period. Avanza Fonder AB purchased a new position in shares of Corbus Pharmaceuticals in the fourth quarter worth approximately $84,000. Deutsche Bank AG raised its holdings in shares of Corbus Pharmaceuticals by 46.8% during the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 2,616 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Corbus Pharmaceuticals in the 4th quarter valued at approximately $101,000. Institutional investors and hedge funds own 64.64% of the company’s stock.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Read More
- Five stocks we like better than Corbus Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Can TikTok Stock Picks Really Make You Rich?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- The “Quality” Rotation: Back to Basics Investing
- What Does a Stock Split Mean?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.